Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Decreased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. cut its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 7.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 958 shares of the company’s stock after selling 81 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Krystal Biotech were worth $153,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of KRYS. Crossmark Global Holdings Inc. increased its stake in Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock worth $362,000 after purchasing an additional 121 shares in the last quarter. Perigon Wealth Management LLC increased its position in shares of Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock worth $1,200,000 after acquiring an additional 123 shares in the last quarter. KBC Group NV increased its position in shares of Krystal Biotech by 25.9% in the third quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after acquiring an additional 132 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Krystal Biotech by 3.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock valued at $840,000 after acquiring an additional 153 shares during the period. Finally, Pier 88 Investment Partners LLC lifted its position in shares of Krystal Biotech by 5.1% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 3,530 shares of the company’s stock valued at $643,000 after acquiring an additional 170 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Trading Up 2.9 %

NASDAQ KRYS opened at $155.75 on Friday. Krystal Biotech, Inc. has a 1-year low of $107.50 and a 1-year high of $219.34. The firm’s fifty day simple moving average is $159.73 and its 200-day simple moving average is $176.66. The company has a market capitalization of $4.48 billion, a PE ratio of 87.99 and a beta of 0.84.

Analyst Upgrades and Downgrades

Several research firms have weighed in on KRYS. HC Wainwright reiterated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. Citigroup lifted their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Chardan Capital reissued a “buy” rating and issued a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $206.67.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).